NASDAQ:IMGO Imago BioSciences (IMGO) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free IMGO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$36.01▼$36.0150-Day Range$35.78▼$36.0152-Week Range$11.56▼$36.09VolumeN/AAverage Volume171,367 shsMarket Capitalization$1.22 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Imago BioSciences alerts: Email Address Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Imago BioSciences Stock (NASDAQ:IMGO)Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Read More Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy IMGO Stock News HeadlinesApril 13, 2024 | msn.comImago Theatre aims to find out if time-traveling Neanderthals have answers to climate changeApril 2, 2024 | seekingalpha.comMerck: Better Times Ahead On Approvals And OutlookApril 27, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.February 23, 2024 | benzinga.comClarus Lifesciences III, L.P.'s Net WorthDecember 21, 2023 | morningstar.comAnixa Biosciences Inc ANIXFebruary 23, 2023 | benzinga.comHarmony Biosciences shares are trading lower after the company reported Q4 financial results.January 11, 2023 | markets.businessinsider.comMerck To Complete Acquisition Of ImagoJanuary 11, 2023 | finance.yahoo.comMerck Completes Tender Offer to Acquire Imago BioSciences, Inc.April 27, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.January 4, 2023 | msn.comLooking Into Imago BioSciences's Recent Short InterestDecember 30, 2022 | seekingalpha.comMerck is best performing large U.S. pharma of 2022December 20, 2022 | finance.yahoo.comImago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in MyelofibrosisDecember 13, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, IMGO, GRAY, USERDecember 12, 2022 | finance.yahoo.comImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022December 12, 2022 | finance.yahoo.comImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022December 12, 2022 | markets.businessinsider.comMerck Commences Tender Offer To Acquire Imago BioSciencesDecember 9, 2022 | msn.comHow Is The Market Feeling About Imago BioSciences?November 30, 2022 | seekingalpha.comImago BioSciences: The Bone Marrow Cancer Researcher Reaches MilestoneNovember 30, 2022 | finance.yahoo.comImago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid LeukemiaNovember 29, 2022 | finance.yahoo.comHorizon Therapeutics Fields Takeover Interest From Pharma GiantsNovember 29, 2022 | benzinga.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Imago BioSciences, Inc. - IMGONovember 28, 2022 | markets.businessinsider.comAnalyst Ratings for Imago BioSciencesNovember 25, 2022 | finance.yahoo.comPharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New IndicationNovember 24, 2022 | 247wallst.comImago Bio Shares Soar on Agreement to Selll to Merck for $1.35 Billion CashNovember 22, 2022 | markets.businessinsider.comExpert Ratings for Imago BioSciencesNovember 22, 2022 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Imago BioSciencesNovember 22, 2022 | finance.yahoo.comImago (IMGO) Shares Surge 104% on Buyout Offer From MerckSee More Headlines Receive IMGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imago BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMGO CUSIPN/A CIK1623715 Webwww.imagobio.com Phone415-529-5055FaxN/AEmployees27Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.85% Return on Assets-30.07% Debt Debt-to-Equity RatioN/A Current Ratio13.15 Quick Ratio13.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.40 per share Price / Book5.63Miscellaneous Outstanding Shares33,822,000Free Float28,783,000Market Cap$1.22 billion OptionableNot Optionable Beta2.82 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Hugh Young Rienhoff Jr. (Age 70)M.D., CEO & Director Comp: $701.78kMs. Laura G. Eichorn (Age 51)Chief Financial Officer Comp: $456.06kMr. Michael H. Arenberg J.D. (Age 53)M.B.A., Chief Operating & Bus. Officer Ms. Hsiangyi Chiang (Age 56)Sr. VP of Fin. & Principal Accounting Officer Dr. Amy E. Tapper Ph.D. (Age 52)Chief of Technical Operations Ms. Jennifer Peppe (Age 53)Global Head of Clinical Operations More ExecutivesKey CompetitorsPacira BioSciencesNASDAQ:PCRXVerona PharmaNASDAQ:VRNACTI BioPharmaNASDAQ:CTICSpyre TherapeuticsNASDAQ:SYREDeciphera PharmaceuticalsNASDAQ:DCPHView All Competitors IMGO Stock Analysis - Frequently Asked Questions How were Imago BioSciences' earnings last quarter? Imago BioSciences, Inc. (NASDAQ:IMGO) announced its earnings results on Wednesday, November, 10th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.10. When did Imago BioSciences IPO? Imago BioSciences (IMGO) raised $105 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 7,000,000 shares at $14.00-$16.00 per share. This page (NASDAQ:IMGO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imago BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
